Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2025 / December / AI Models Predict CNS Tumors From Spinal Fluid
Oncology Molecular Pathology Digital and computational pathology Liquid biopsy Omics

AI Models Predict CNS Tumors From Spinal Fluid

At AMP 2025, a South Korean research team outlined a multimodal approach that integrates CSF, DNA, and MRI data to enable early, noninvasive tumor classification.

12/04/2025 News 1 min read

Share

Credit: iStock

Artificial intelligence (AI) models may allow earlier noninvasive identification of pathogenic variants in central nervous system (CNS) tumors, according to researchers presenting new data at the Association for Molecular Pathology (AMP) annual meeting. By integrating genetic and imaging data, the models could help clinicians anticipate tumor biology and guide treatment before surgical tissue is available.

The study, conducted by a team from Soonchunhyang University in South Korea, was presented Saturday by Jieun Kim, MD, PhD, at AMP 2025 in Boston. The researchers developed 2 machine-learning models: a dense neural network trained on mutation data from 12 key genes using next-generation sequencing of cerebrospinal fluid (CSF)–derived circulating tumor DNA, and a convolutional neural network trained on standardized magnetic resonance imaging (MRI) images. Data were drawn from paired tissue, CSF, and MRI data sets from patients with CNS tumors. The researchers used averaging or majority voting to combine the models’ outputs, optimizing diagnostic robustness.

The models classified samples into 3 categories—glial tumors (GBM), nonglial CNS tumors, and normal tissue—with strong reliability. Misclassifications occurred mostly between glial and nonglial tumors, whereas normal samples were consistently identified. Each model independently achieved high classification accuracy—the dense neural network showed a Matthews Correlation Coefficient (MCC) of 0.8822, whereas the MRI-based convolutional network achieved an MCC of 0.8525. Combining the outputs further improved performance, showing high consistency in identifying pathogenic variants and tumor type.

The findings suggest that multimodal AI may enhance precision neuro-oncology by offering a noninvasive, preoperative tool for mutation detection and histologic classification. Integration of genetic and imaging features could shift clinical workflows toward earlier intervention and personalized treatment planning, reducing reliance on repeated, invasive biopsies, Dr. Kim said.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Redefining Diagnostic Reference Standards
Molecular Pathology
Redefining Diagnostic Reference Standards

January 3, 2022

1 min read

Find out what Horizon Discovery’s diagnostic reference standards can do for your workflow

Non-invasive Prostate Cancer Screening
Molecular Pathology
Non-invasive Prostate Cancer Screening

November 5, 2014

1 min read

Can SERS accurately detect the early stages of the most common male cancer?

Sequencing Access for All
Molecular Pathology
Sequencing Access for All

January 24, 2022

1 min read

An affordable genome sequencing pipeline for low- and middle-income countries

Improving Risk Stratification
Molecular Pathology
Improving Risk Stratification

February 3, 2022

1 min read

Two genes have been identified that may be linked to prostate cancer outcomes

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.